Nimedine

Quick links to important sections

Nimedine

Method of action: Bactericidal

Treatment option: Endocarditis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nimedine

What is Nimedine? Defining the Core Identity

Property Description
Active ingredient Imipenem and Cilastatin
Form Sterile powder for injection/infusion
Pharmacological class Carbapenem antibiotic
Common use Systemic treatment of severe bacterial infections
Origin Imipenem is a semisynthetic derivative of Thienamycin

Nimedine is a commercial brand name for a potent fixed-combination drug whose active ingredients are the antibiotic Imipenem and the enzyme inhibitor Cilastatin. This medicine is classified as a broad-spectrum anti-infective agent, belonging to the Carbapenem class of beta-lactam antibiotics, which is reserved for treating serious, complex bacterial infections. Imipenem and Cilastatin for Injection is a sterile formulation that must be administered parenterally via injection or intravenous infusion.

This class is globally clinically recognized for its wide range of activity against diverse bacterial types. Nimedine, in its specific form, is one brand used for critical care scenarios requiring a potent, hospital-administered antibiotic, with other common combinations sharing this formulation being marketed under brand names such as Primaxin or Tienam.


Composition: The Essential Dual Components (Imipenem and Cilastatin)

The efficacy of Nimedine is based on its dual composition. Imipenem is the semisynthetic antibacterial component, derived from the natural product Thienamycin, which performs the direct killing of bacteria by inhibiting cell wall synthesis. The second component is Cilastatin, which functions as a non-antibiotic renal dipeptidase inhibitor.

Cilastatin is necessary to protect the Imipenem molecule from rapid breakdown by a specific kidney enzyme (dehydropeptidase I). By blocking this enzyme, Cilastatin ensures that the active Imipenem is maintained at adequate levels for a longer duration to effectively target pathogens throughout the body.


General Purpose: Why is a Carbapenem Combination Used?

The potent dual action is utilized to provide a reliable solution for controlling bacterial proliferation in severe, complicated infections where traditional antibiotic options may fail. For instance, in a typical neutral use scenario, Nimedine might be employed to treat patients with bacterial septicemia or complicated intra-abdominal infections. Its broad-spectrum nature means it is effective against a vast range of pathogens, establishing its role as a powerful, prescription-only (Rx) agent for systemic infection control.

Regulatory References

  1. NIH PubChem entry for Imipenem-Cilastatin

What side effects are possible with Nimedine?

Possible Side Effects and Safety Information

The safety profile for Nimedine (Imipenem and Cilastatin) is categorized by regulatory bodies based on the frequency and the physiological systems affected, ensuring a standardized, descriptive overview of potential adverse reactions. The medicine is primarily associated with reactions across the Central Nervous System (CNS), Gastrointestinal (GI) system, and Immune System.


Frequency and System-Organ Classifications

Adverse reactions are formally classified by frequency in official labeling. Common reactions (affecting 1% to 10% of patients) typically include nausea, vomiting, diarrhea, and local reactions like phlebitis (vein inflammation) at the injection site. Uncommon reactions (affecting 0.1% to 1%) documented in regulatory texts include seizures, dizziness, and confusional states.

Serious adverse reactions that are specifically highlighted in official warnings include immediate, life-threatening anaphylactic reactions and severe seizures. The development of Clostridioides difficile-associated diarrhea (CDAD) is also a documented serious adverse reaction.


Population-Specific Safety Notes

The prescribing information notes specific safety considerations for certain populations. Patients with pre-existing impaired renal function or a history of CNS disorders have a documented increased risk of CNS-related adverse effects, including seizures. Furthermore, the label advises that the potential for CDAD can persist up to several months following the completion of treatment. Nimedine is contraindicated in individuals with known hypersensitivity to the drug's components or to other antibiotics in the beta-lactam class, such as penicillins or cephalosporins. Concomitant use with Valproic Acid is generally not recommended as it can lead to a reduction in therapeutic drug levels and an increased risk of breakthrough seizures.

Overdose and Emergency Response

Overdosage with Nimedine (Imipenem and Cilastatin) primarily affects the Central Nervous System. Documented clinical manifestations of overexposure include confusion, seizures (convulsions), myoclonic activity (muscle jerks/tremors), and drooping eyelids. Regulator guidance defines these presentations as potentially life-threatening symptoms requiring immediate attention.

In the event of a suspected overdose, it is mandated to seek immediate emergency medical attention. Specifically, emergency services must be contacted immediately if the affected individual experiences collapse, trouble breathing, a seizure, or cannot be awakened, as these are critical outcomes described in the official labeling.

Regulatory documentation states that the management of Nimedine overdosage is limited to symptomatic and supportive treatment, as there is no specific antidote documented in the prescribing information. While the components are dialyzable, the clinical usefulness of hemodialysis in this specific setting is noted to be questionable.

A crucial population-specific risk identified in official labeling concerns renal impairment. Adult patients with creatinine clearances of 30 mL/min or less have a documented higher risk of seizure activity following overexposure. Additionally, convulsions and oliguria (reduced urine output) are noted as reactions in neonates and infants up to three months of age in overdose situations.

Therapeutic Uses of Nimedine

What Nimedine Treats: Main Uses and Benefits

Nimedine (Imipenem and Cilastatin) is a broad-spectrum anti-infective agent reserved for the systemic treatment of severe and complex bacterial infections. Its primary role is considered relevant for support in addressing the infectious cause in critical situations.


The medication is commonly used for managing severe conditions presenting with systemic or localized discomfort, including bacterial septicemia (sepsis), infections of the heart lining (endocarditis), deep intra-abdominal abscesses, complicated pneumonia, and aggressive bone and soft-tissue infections. Its use provides support that helps ease the overall symptom burden by being applied across domains where additional symptomatic support is needed in the presence of entrenched pathogens.

“The primary goal of using this agent is to gain control of bacterial proliferation in serious, life-threatening scenarios.”

This antibiotic is relevant in contexts involving heightened systemic burden, often used in critical care settings and for hospital-acquired infections, especially when pathogens are suspected to be multidrug-resistant. Its application during these phases of increased distress contributes to maintaining a sense of stability and is applied in addressing symptom clusters that may become intense or disruptive, which is relevant when supportive symptom management is appropriate.


Quick Fact: Relief for Systemic Discomfort
Nimedine assists with maintaining functional stability and supports patients during episodes of heightened discomfort caused by conditions associated with acute or disruptive episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nimedine?

Official regulatory documents establish clear population eligibility criteria for Nimedine (Imipenem and Cilastatin).

Populations for whom use is Contraindicated:

  • Patients with documented hypersensitivity to Imipenem, Cilastatin, any other carbapenem antibacterial agent, or those with a history of severe allergic reaction to any beta-lactam antibiotic.
Age-Related Eligibility and Restrictions: Age Group Regulatory Rule
Adults Use is established under standard labeled conditions.
Children Established for ages ge 3 months.
Infants / CNS Infection Not recommended for children under 3 months of age or for pediatric patients with Central Nervous System (CNS) infections (e.g., meningitis).

Condition-Specific Eligibility Rules:

  • Severe Renal Impairment: Use is not recommended for patients with a Creatinine Clearance ( CrCl) of le 15 mL/min unless hemodialysis is immediately initiated. Dose adjustment is mandatory for all patients with CrCl le 90 mL/min.
  • CNS Disorders: Patients with a history of seizures or other pre-existing CNS disorders must use the medicine with caution.

Pregnancy and Lactation Eligibility Status:

  • Safety during pregnancy and lactation is not established due to insufficient human data. Use is only permitted if the potential clinical benefit is determined to outweigh the potential risk.

Connection to the overall eligibility profile: Regulatory agencies define eligibility primarily through immunological status (ruling out use in allergic populations) and the status of renal function (determining conditional use or absolute prohibition). These explicit criteria guide who can and cannot use the medicine safely according to the approved labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nimedine (Imipenem and Cilastatin) has officially documented interaction patterns that establish constraints on co-administration with specific medicinal products.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Official Interaction Outcome Regulatory Restriction
Valproic Acid / Divalproex Sodium Reduction in serum concentrations of the anticonvulsant, raising the risk of breakthrough seizures. Concomitant use is generally not recommended due to increased safety risk.
Ganciclovir Increased risk of generalized seizures/convulsions due to augmented central nervous system (CNS) toxicity. Co-administration is not recommended unless specific benefits outweigh risks.
Probenecid Increased systemic exposure (plasma levels and half-life) of Imipenem by officially decreasing its renal clearance. Use requires recognition of the pharmacokinetic interaction.

Administration and Population Notes

Co-administration with live bacterial vaccines is documented to decrease the vaccine's effect, requiring careful consideration of timing of administration. Additionally, patients with underlying CNS disorders or impaired renal function are noted in official labeling to have a heightened susceptibility to the adverse CNS outcomes (seizures) associated with the Valproic Acid and Ganciclovir interactions. No specific interactions with food, alcohol, or herbal products are formally documented across core regulatory prescribing information.

Mechanism of Action

How Nimedine Works

Nimedine, a fixed-combination agent of Imipenem and Cilastatin, functions through two distinct, synergistic mechanisms that ensure the molecular integrity of the antibiotic and its targeted action against bacteria.

Disruption of Bacterial Cell Wall Synthesis

The primary action involves Imipenem, which acts as an inhibitor of bacterial enzymes known as Penicillin-Binding Proteins (PBPs), specifically transpeptidases. These PBPs are critical for the final stage of peptidoglycan cross-linking, which confers rigidity to the bacterial cell wall. The molecular interaction initiates a mechanistic sequence: PBP inactivation compromises the structural integrity of the cell wall, leading to osmotic instability and rapid cell lysis and death. This destruction of bacterial structure is the core physiological action resulting in the systemic clearance of susceptible bacteria.

Protection of Drug Integrity within the Host

Cilastatin, the non-antibiotic component, supports this activity by functioning as a competitive inhibitor of the host renal enzyme Dehydropeptidase-I (DHP-I). By blocking DHP-I, Cilastatin prevents the premature hydrolysis and inactivation of Imipenem in the kidney, thereby maintaining sustained systemic drug concentrations required to enable binding and inhibition of the bacterial PBPs throughout the body.

Dosage and Administration Information

How Nimedine is Used: Official Administration Guidelines

Nimedine (Imipenem and Cilastatin) is a combination agent administered under specialist supervision, primarily in hospital settings, following specific instructions for its parenteral use. The drug is supplied as a sterile powder that requires reconstitution and further dilution with an appropriate intravenous fluid before use.


Administration and Dosage Schedules

Use Parameter Official Guideline Population-Specific Rule
Route Intravenous (IV) Infusion is the principal route; intramuscular (IM) use is approved in some countries. Administered after hemodialysis for patients on dialysis.
Standard Adult Dose 500 mg/500 mg every 6 hours (q6h) OR 1000 mg/1000 mg every 8 hours (q8h). The total daily dose should not exceed 4000 mg/4000 mg.
Infusion Duration Doses le 500 mg must be given over 20 to 30 minutes. Doses > 500 mg must be infused over 40 to 60 minutes.

Adjustments for Specific Populations

Dose Reduction for Renal Impairment: A mandatory reduction in dose and/or extension of the dosing interval must be made for adult patients whose creatinine clearance is less than 90 mL/min. The specific reduced dose depends on the patient's degree of renal impairment.

Pediatric Dosing: For pediatric patients one year of age and older, the dose is determined based on body weight (mg/kg) and administered at fixed intervals, typically q6h. No dose adjustment is generally required for older patients with normal renal function for their age.

Following reconstitution, the prepared solution must be infused slowly and completely. The total duration of therapy is guided by the patient's clinical response and the nature of the condition being managed.

Recent Clinical Evidence

Research evidence / Overview of Studies for Nimedine

The evidence base for Nimedine (Imipenem and Cilastatin) is built primarily on Randomized Controlled Trials (RCTs) and systematic analyses that review these trials. The evidence base for Nimedine includes numerous controlled studies evaluating its use in regulatory-approved indications. Findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.


Evidence for Use in Severe, Complicated Systemic Infections

Research has explored Nimedine's use in systemic conditions like septicemia and severe pneumonia. Studies were conducted during periods of increased symptom activity and monitored measured endpoints, including clinical status and pathogen presence. The outcomes related to systemic or functional imbalance were studied for this medicine in numerous trials.

Studies report how symptoms evolved in the observed populations. Trials described patterns related to the assessed endpoints of clinical status change and microbiological status change in the study cohorts. However, some comparative systematic reviews have described patterns indicating that outcomes related to clinical status assessed in those studies appeared different from those observed for certain newer types of antibiotics in the same class.


Evidence in Special Patient Populations

Research examined Nimedine in both older adults and pediatric patients, though data for certain groups remain insufficient. Findings for these populations describe group patterns but often come from smaller or post-regulatory studies.

Research also explored outcomes in cohorts of patients with reduced kidney function. Studies monitored outcomes linked to inflammatory or irritative states and changes in biomarkers related to kidney health in these specific patient groups.


Gaps in the Evidence and Areas for Future Study

While the evidence base for Nimedine is large, research is ongoing, and evidence remains limited in certain specific areas. The research record indicates that a notable limitation is the population selectivity of many older studies. The protocols often excluded the most critically ill patients or those whose immediate condition precluded participation in the study. This means the results apply only to the populations studied, and the research provides limited insight into outcomes for the highest-risk, most unstable critical care patients. The research highlights what is known, and what is still uncertain regarding the full scope of use.

Key Studies & References

  1. Imipenem and Cilastatin Injection: MedlinePlus Drug Information
  2. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections

Frequently Asked Questions (FAQ)

Common questions about Nimedine (FAQ)

Q: What is Nimedine used for besides the main condition?

Official regulatory indications specify that Nimedine is approved for treating several serious conditions.

These include infections of the Lower Respiratory Tract, Urinary Tract, Intra-Abdominal and Gynecologic systems, as well as Bacterial Septicemia, Bone and Joint Infections, and Skin and Skin Structure Infections.

Q: Can Nimedine cause excessive tiredness or fatigue?

Official drug labeling reports that some patients experience unusual tiredness or weakness as a less common side effect.

Q: Are the side effects of Nimedine permanent?

Official warnings note that a serious adverse reaction, Clostridioides difficile-associated diarrhea (CDAD), can occur up to several weeks or months after treatment has been completed.

Q: Is it normal to feel a change in heart rate after starting Nimedine?

Reports of a change in heart rate, such as palpitations or a rapid heart rate (tachycardia), are listed in official documents as rare adverse reactions.

Q: Does Nimedine cause any issues with memory or concentration?

Regulatory documents report Central Nervous System (CNS) adverse effects, including confusional states and drowsiness (somnolence).

These effects are related to the nervous system and may influence a patient's cognitive status.

Q: How quickly should I expect to notice the effects of Nimedine?

According to official pharmacokinetic information, the active component of Nimedine (Imipenem) reaches peak plasma levels in the bloodstream shortly after the intravenous infusion is complete.

However, the exact time it takes for a patient to observe a clinical response varies based on the type and severity of the infection being treated.

Q: Does Nimedine need to be taken at the exact same time every day?

Nimedine is prescribed at fixed, regular intervals (such as every six or eight hours) to ensure a steady concentration of the medicine is maintained in the blood.

This consistent schedule is important for the medicine to effectively target the infection, as it helps maintain steady drug concentrations.

Q: If I stop taking Nimedine, will the original condition return immediately?

Official patient counseling information indicates that the medicine is typically prescribed for a full course of treatment, even if symptoms improve. Stopping therapy prematurely may prevent the infection from being completely cleared.

Q: What is the expected long-term duration of Nimedine use?

The duration of therapy is not a fixed period and is determined by a healthcare provider based on the type and severity of the patient's infection.

Regulatory information indicates the medicine is intended to be administered for the full time of treatment determined by a healthcare provider.

Q: Are there different restrictions for men and women using Nimedine?

Regulatory documents indicate no specific differences or restrictions for the use of Nimedine in adult men versus women.

Restrictions for women are specifically related to the status of pregnancy and lactation.

Q: Is the brand-name Nimedine different from the generic version?

Nimedine is a commercial brand name for the combination of the active ingredients Imipenem and Cilastatin.

Both brand-name and generic products contain the same active components and are supplied as a sterile powder for injection.

Q: Does Nimedine require any special monitoring or regular blood tests?

The prescribing information notes that changes in certain lab tests have been reported. These include markers for liver function (enzyme levels) and kidney function (creatinine).

Patients are also monitored for adverse effects such as seizure activity.

Q: Does Nimedine affect liver function?

Official labeling confirms that changes in liver enzyme levels and bilirubin have been reported as adverse reactions.

While rare, hepatitis (liver inflammation) and liver failure have also been noted in regulatory documents.

Q: How long does Nimedine stay in your system after stopping?

Official pharmacokinetic data for the active components indicate that the plasma half-life is approximately one hour in people with normal kidney function.

The half-life describes the time required for the amount of medicine in the blood to decrease by half.

Q: Are there any mental health side effects associated with Nimedine?

Central Nervous System adverse reactions documented in official labeling include confusion, agitation, delirium, disorientation, and hallucinations.

Q: Can Nimedine be split or crushed?

No. Nimedine is supplied as a sterile powder that requires reconstitution for intravenous injection or infusion and is therefore not intended to be taken orally or manipulated by splitting.

Q: Does Nimedine interfere with the effectiveness of birth control?

The interaction section does not specifically list hormonal birth control. However, official patient counseling information suggests that patients using this antibiotic discuss with their healthcare provider whether additional reliable birth control methods may be necessary during treatment.

Q: Can Nimedine affect my ability to drive or operate machinery?

Official warnings note that the drug may cause CNS side effects such as dizziness, somnolence (drowsiness), and seizures.

Because of these potential effects, the ability to perform tasks requiring mental alertness, like driving or operating machinery, may be impaired.

Q: What are the signs of a severe allergic reaction to Nimedine?

Signs of a severe allergic reaction (anaphylaxis) are noted in official labeling as requiring immediate attention.

These signs include hives, trouble breathing or wheezing, hoarseness, trouble swallowing, or swelling of the face, lips, tongue, or throat.

Q: Does Nimedine affect sleep patterns?

Official adverse reaction reports list somnolence as a possible side effect. Somnolence is the regulatory term for drowsiness.

How should Nimedine be stored and disposed of?

How to Store and Dispose of Nimedine?

This section outlines the mandatory storage and disposal rules for Nimedine (Imipenem and Cilastatin) as defined by official regulatory labeling.


Storage Requirements

Item Requirement
Unopened Powder Store at controlled room temperature (up to 25 C) and protect from moisture. Must be kept in the original, tightly closed container.
Reconstituted Solution Must be used immediately or stored under refrigeration (2 C to 8 C) for a limited time (e.g., 24 hours). The solution must not be frozen.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Nimedine product must be disposed of in accordance with local pharmaceutical waste regulations. The medicine must not be thrown into household trash or disposed of via wastewater (e.g., flushing).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nimedine found in:

A-Z Index: